The NMDA receptor antagonist ketamine can induce a rapid improvement in depressive symptoms that often endures for days after a single intravenous dose. The pharmacodynamic basis for this effect is poorly understood. Using a proton magnetic resonance spectroscopy ([ 1 H]-MRS) method that previously detected a normalization of amino acid neurotransmitter (AANt) content after chronic treatment with conventional antidepressant treatments, we examined whether the acute action of ketamine is associated with alterations in AANt content as well. Ten subjects with major depressive disorder (MDD) received saline, then ketamine in a fixed order, one week apart, under single-blind conditions. Each infusion was associated with three [ 1 H] MRS scans (baseline, 3 h and 48 h post-infusion) that measured glutamate, GABA and glutamine within the occipital cortex. Rating scales were administered before, during and after each infusion. The rapid (1 h) and sustained (at least 7 days) antidepressant effect we observed after ketamine infusion was not associated with either baseline measures of, or changes in, occipital AANt content. Dissociative symptoms were not correlated with changes in depression scores. While our results indicate that changes in occipital AANt content are not a correlate of ketamine's antidepressant action, this may only apply to the regional and temporal windows of our MRS measurements.
The NMDA receptor antagonist ketamine can induce a rapid improvement in depressive symptoms that often endures for days after a single intravenous dose. The pharmacodynamic basis for this effect is poorly understood. Using a proton magnetic resonance spectroscopy ([ 1 H]-MRS) method that previously detected a normalization of amino acid neurotransmitter (AANt) content after chronic treatment with conventional antidepressant treatments, we examined whether the acute action of ketamine is associated with alterations in AANt content as well. Ten subjects with major depressive disorder (MDD) received saline, then ketamine in a fixed order, one week apart, under single-blind conditions. Each infusion was associated with three [ 1 H] MRS scans (baseline, 3 h and 48 h post-infusion) that measured glutamate, GABA and glutamine within the occipital cortex. Rating scales were administered before, during and after each infusion. The rapid (1 h) and sustained (at least 7 days) antidepressant effect we observed after ketamine infusion was not associated with either baseline measures of, or changes in, occipital AANt content. Dissociative symptoms were not correlated with changes in depression scores. While our results indicate that changes in occipital AANt content are not a correlate of ketamine's antidepressant action, this may only apply to the regional and temporal windows of our MRS measurements. © 2010 Elsevier Ireland Ltd. All rights reserved.
Introduction
Innovation in the clinical therapeutics of major depressive disorder (MDD) may be derived from revised pathophysiological models that incorporate the accumulating evidence for a role of dysregulated glutamatergic neurotransmission. Indeed, both preclinical and clinical studies have demonstrated that a variety of glutamatergic compounds have antidepressant effects (Sanacora et al., 2008; Machado-Vieira et al., 2009) . In particular, the N-methyl-D-aspartate receptor (NMDAR) antagonist ketamine has emerged as a leading prototype for antidepressant development because it can be both rapidly acting and efficacious in 'treatment-resistant' MDD subjects (i.e. those without an adequate clinical response to monoaminergic drugs) (Berman et al., 2000; Zarate et al., 2006; Mathew et al., 2009 ). Furthermore, the antidepressant effect induced by a single, intravenous administration of ketamine often endures for days, well beyond the transient changes in perception and cognition commonly observed during an infusion of a subanesthetic dose. The identification of how this relatively brief pharmacological blockade of the NMDAR induces a rapid and sustained improvement in depressive symptoms would have important theoretical and practical implications.
Preclinically, NMDAR antagonists induce a variety neurophysiological effects implicated in antidepressant action including the modulation of monoaminergic neurotransmission (Paul et al., 1992; Dall'Olio et al., 1999) , the enhancement of both hippocampal neurogenesis (Gould et al., 1997; Nacher et al., 2001 Nacher et al., , 2003 Keilhoff et al., 2004) and long-term potentiation (Buck et al., 2006) , and increased hippocampal brain-derived neurotrophic factor (BDNF) levels (Garcia et al., 2008) . In addition, recent studies suggest that increased alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-receptor-mediated synaptic potentiation and subsequent activation of the mTOR signaling pathway initiate the physiological responses that generate ketamine's antidepressantlike actions in rodent models (Maeng et al., 2008; Li et al., 2010) . These studies are in line with a previous report showing that ketamine acutely increases glutamatergic neurotransmission in the prefrontal cortex of rodents (Moghaddam et al., 1997) , and collectively, these 
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